Safety of opioids and benzodiazepines in patients with breathlessness and respiratory failure associated with Chronic Obstructive Pulmonary Disease
More details
Hide details
Dept of Pneumonology, Medical School, Democritus University of Thrace, Greece
Demosthenes Bouros   

Dept of Pneumonology, Medical School, Democritus University of Thrace, Greece Alexandroupolis 68100
Pneumon 2014;27(3):197–199
American Thoracic Society. Dyspnea: mechanisms, assessment, and management. A consensus statement. AJRCCM 1999; 159:321–40.
Edmonds P, Karlsen S, Khan S, et al. A comparison of the palliative care needs of patients dying from chronic respiratordiseases and lung cancer. Palliat Med 2001;15:287-95.
Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manage 2006;31:58-69.
Simon ST, Higginson IJ, Booth S, et al. Benzodiazepines for the relief of breathlessness in advanced malignant and nonmalignant diseases in adults. Cochrane Database Syst Rev. 2010 CD007354.
Jennings AL, Davies AN, Higgins JP, et al. A systematic review of the use of opioids in the management of dyspnoea. Thorax 2002;57:939-44.
Abernethy AP, Currow DC, Frith P, et al. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ 2003;327:523-8.
Brown SJ, Eichner SF, Jones JR. Nebulized morphine for relief of dyspnea due to chronic lung disease. Ann Pharmacother 2005;39:1088-92.
Rocker G, Horton R, Currow D, et al. Palliation of dyspnoea in advanced COPD: Revisiting a role for opioids. Thorax 2009;64:910- 5.
Mahler DA, Selecky P, Harrod CG, et al. American College of Chest Physician’s consensus statement on the management of dyspnea in patients with advanced lung or heart disease. Chest 2010;137:674-91.
Young J, Donahue M, Farquhar M, et al. Using opioids to treat dyspnea in advanced COPD: attitudes and experiences of family physicians and respiratory therapists. Can Fam Physician 2012;58:401-7.
Chan JD, Treece PD, Engelberg RA, et al. Narcotic and benzodiazepine use after withdrawal of life support: association with time to death? Chest 2004;126:286-93.
Jennings AL, Davies AN, Higgins JP, et al. Opioids for the palliation of breathlessness in terminal illness. Cochrane Database Syst Rev 2001;4:CD002066.
Ekström MP, Bornefalk-Hermansson A, Abernethy AP, et al. Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study. BMJ 2014;348.
Rocker GM, Dodek PM, Heyland DK. Toward optimal end-of-life care for patients with advanced chronic obstructive pulmonary disease: Insights from a multicentre study. Can Respir J 2008;15:249–54.
Currow DC, McDonald C, Oaten S, et al. Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study. J Pain Symptom Manage 2011;42:388-99.
Charlson F, Degenhardt L, McLaren J, et al. A systematic review of research examining benzodiazepine-related mortality. Pharmacoepidemiol Drug Saf 2009;18:93-103.
Johnson MJ, Bland JM, Oxberry SG, et al. Opioids for chronic refractory breathlessness: patient predictors of beneficial response. Eur Respir J 2013;42:758-66.
Marciniuk DD, Goodridge D, Hernandez P et al. Canadian Thoracic Society COPD Committee Dyspnea Expert Working Group. Managing dyspnea in patients with advanced chronic obstructive pulmonary disease: a Canadian Thoracic Society clinical practice guideline. Can Respir J 2011;18:69-78.
Qaseem A, Snow V, Shekelle P, et al. For the Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Evidence-based interventions to improve the palliative care of pain, dyspnea, and depression at the end of life: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008;148:141–6.